Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging tool may help detect Eye-Area skin cancer without a biopsy

NCT ID NCT06279143

Diagnosis Sponsor: Vejle Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a non-invasive imaging device called dermal optical coherence tomography (D-OCT) to diagnose basal cell carcinoma (a common skin cancer) around the eye area. Researchers compared its accuracy to standard biopsy results in 210 adults with suspected lesions. The goal was to see if D-OCT could reliably detect and classify these cancers without needing a tissue sample.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

210 people

The number who actually took part.

Started

Apr 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive enrolment of newly referred patients under the diagnosis "clinically suspected BCC" in the periocular area

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically suspected periocular BCC. * Biopsy-verified BCC * Clinically suspected relapse of periocular BCC * Age more than 18 years at baseline. * Legally competent, able to give verbal and written consent * Communicate in Danish verbally as well as in writing * Willingness to participate and able to give informed consent and can comply with protocol requirements. Exclusion Criteria: * Anatomical circumstances that make OCT-scanning impossible, i.e., extensive scarring of eyelids, or large ulcerating crusts that hampers scanning * Unwillingness to undergo a skin biopsy or excision of lesion. * Inability to sign informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease basal cell carcinoma carcinoma epithelial neoplasm eyelid disorder eyelid neoplasm Recurrence skin basal cell carcinoma skin disorder skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCC BCC - basal cell carcinoma Eyelid diseases Eyelid tumor Skin diseases

Contacts and locations

Locations

  • Department of Ophthalmology, University Hospital of Southern Denmark, Vejle Hospital

    Vejle, Region of Southern Danmark, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.